Hikal is currently trading at Rs. 618.00, up by 8.30 points or 1.36% from its previous closing of Rs. 609.70 on the BSE.
The scrip opened at Rs. 614.00 and has touched a high and low of Rs. 625.50 and Rs. 611.00 respectively. So far 438 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 656.00 on 21-Jul-2014 and a 52 week low of Rs. 386.50 on 31-Jul-2013.
Last one week high and low of the scrip stood at Rs. 650.00 and Rs. 605.70 respectively. The current market cap of the company is Rs. 1016.00 crore.
The promoters holding in the company stood at 68.77% while Institutions and Non-Institutions held 13.45% and 17.78% respectively.
Hikal has successfully completed an inspection by European Directorate for the Quality of Medicines (EDQM) at its manufacturing facility at Bangalore. The primary focus of the inspection was the adherence to compliance and implementation of a suitable Quality Management System based on the Good Manufacturing Practice as laid down in the EU Rules governing Medicinal products in the European Union.
The inspection concluded that the company operated in accordance with the rules and regulations of the governing authorities based in the European Union and Hikal’s adherence to the highest standards of product quality and global regulatory compliance procedures as part of its fundamental value system. The successful completion of this audit is a positive reflection of company’s people, systems and procedures and commitment to Company's global customer base.
Hikal is a provider of solutions & reliable long-term outsourcing partner to companies in the Pharmaceuticals, Crop Protection, Animal health, and Specialty Chemicals industry. The company has been supplying key active ingredients (AI) and intermediates, manufactured using stringent global quality standards, for its customers in the United States, Europe and Japan.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1797.80 |
| Dr. Reddys Lab | 1213.90 |
| Cipla | 1486.30 |
| Lupin | 2069.95 |
| Zydus Lifesciences | 948.70 |
| View more.. | |
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Make an informed decision for Stocks
Invest using an intelligent system with powerful data-driven tools that help you identify opportunities and make informed buy-hold-sell decisions
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Claim your FREE 15-day access to the most practical investing handbook.
Hurry, limited to the first 10 users today!
Become a savvy and confident
stock investor.
Don't miss out! First 10 users today get it FREE
Download APP
